---
id: acog-ectopic-pregnancy-2024
title: "ACOG 2024 Practice Bulletin: Tubal Ectopic Pregnancy"
short_title: "ACOG Ectopic Pregnancy 2024"

organization: American College of Obstetricians and Gynecologists
collaborators: null
country: US
url: https://www.acog.org/clinical-information/clinical-guidance
doi: null
pmid: null
open_access: true

specialty: obstetrics-gynecology
guideline_type: clinical-practice
evidence_system: ACOG
conditions:
  - ectopic pregnancy
  - tubal pregnancy
  - pregnancy of unknown location
tags:
  - methotrexate
  - salpingectomy
  - beta-hCG
  - ultrasound
  - laparoscopy

publication_date: 2024-06-01
previous_version_date: 2018-03-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-26
---

## Scope
2024 ACOG practice bulletin on the diagnosis and management of tubal ectopic pregnancy.

## Key Recommendations

### Diagnosis
- **Clinical Suspicion**: Pelvic pain, vaginal bleeding, positive pregnancy test, risk factors (prior ectopic, PID, tubal surgery).
- **Transvaginal Ultrasound (TVUS)**: Definitive diagnosis if extrauterine gestational sac or embryo with heartbeat. Empty uterus with hCG above discriminatory zone (~1,500-2,000 mIU/mL) is concerning.
- **Serial β-hCG**: Abnormal rise (<53% in 48 hours) suggests abnormal pregnancy (ectopic or miscarriage).

### Management Options

#### Expectant Management
- Select patients with:
  - Declining β-hCG.
  - Low initial β-hCG levels.
  - Asymptomatic.
  - Close follow-up available.
- Not for hemodynamically unstable or unreliable follow-up.

#### Medical Management (Methotrexate)
- **Indications**: Hemodynamically stable, no contraindications to methotrexate, unruptured ectopic, low β-hCG (<5,000 mIU/mL optimal), no fetal cardiac activity, able to comply with follow-up.
- **Regimens**:
  - **Single-Dose**: Methotrexate 50 mg/m² IM. Check β-hCG days 4 and 7; repeat dose if <15% decline.
  - **Two-Dose**: Methotrexate on days 0 and 4.
  - **Multi-Dose**: Alternating methotrexate and leucovorin; reserved for high β-hCG.
- Monitor β-hCG weekly until undetectable.

#### Surgical Management
- **Indications**: Hemodynamic instability, ruptured ectopic, failed medical management, high β-hCG, fetal cardiac activity, contraindication to methotrexate.
- **Laparoscopy (Preferred)**: Salpingectomy (tubal removal) or salpingostomy (tubal preservation). Salpingectomy is standard unless fertility-preserving is strongly desired and tube is minimally damaged.
- **Laparotomy**: If unstable or laparoscopy not feasible.

### Follow-Up
- Monitor β-hCG to undetectable levels post-treatment.
- Counsel on future fertility and recurrence risk.
